A detailed review has shown that most optional add-on treatments used during in vitro fertilisation (IVF) do not have enough evidence to prove that they increase the rates of live births.

詳細評論顯示，體外受精 (IVF) 期間使用的多數選擇性附加治療，缺乏足夠證據證明能提高活產率。

The study, led by the University of Melbourne and published in The Lancet, analyzed 85 high-quality medical trials to test ten common add-on therapies. The researchers found that seven procedures—including acupuncture and certain plasma infusions—either showed no clear effect on fertility or had inconclusive results. In contrast, only three treatments, such as EmbryoGlue and PICSI, showed some weak evidence of benefit, although these results still require careful consideration.

這項由墨爾本大學領銜並發表於《刺針》(The Lancet) 的研究，分析了 85 項高品質醫療試驗，以測試十種常見的附加療法。研究人員發現，包括針灸和某些血漿輸注在內的七種程序，對生育能力沒有明顯影響，或結果不確定。相反，僅有三種治療（如 EmbryoGlue 和 PICSI）顯示出微弱的獲益證據，儘管這些結果仍需謹慎考慮。

There is a clear gap between common clinical practice and evidence-based guidelines. While between 75% and 82% of IVF patients in Australia use these add-ons, the overall success rate remains low at 30–40%. Some doctors claim that these services are popular because of patient demand and social media misinformation. Furthermore, analysts suggest that commercial pressure in the $810 million private fertility industry may encourage clinics to offer unproven treatments. Consequently, patients often assume that if a treatment is available, it must be effective, which leads to unnecessary spending and medical procedures.

常見的臨床實踐與實證指南之間存在明顯差距。雖然澳洲有 75% 至 82% 的 IVF 患者使用這些附加療法，但整體成功率仍維持在 30% 至 40% 的低水平。部分醫生聲稱，這些服務之所以流行，是因為患者的需求以及社交媒體上的錯誤資訊。此外，分析師指出，價值 8.1 億美元的私立生育產業之商業壓力，可能會促使診所提供未經證實的治療。因此，患者往往假設只要有該項治療，就一定是有效的，進而導致不必要的開支與醫療程序。

In response, organizations are calling for better informed consent and stronger regulation. The Fertility Society of Australia and New Zealand (FSANZ) has emphasized the need for national regulations to reduce the risks of marketing non-essential services. To help patients, researchers have created an independent digital resource. Initial tests show that while this data may be emotionally difficult for patients, it significantly improves their understanding of the risks and the lack of evidence for these optional treatments.

對此，相關組織呼籲應提供更完善的知情同意與更強有力的監管。澳洲及紐西蘭生育學會 (FSANZ) 強調需要全國性監管，以降低行銷非必要服務的風險。為了幫助患者，研究人員建立了一個獨立的數位資源。初步測試顯示，雖然這些數據在情感上可能令患者難以接受，但顯著提高了他們對這些選擇性治療之風險及缺乏證據的認識。

Current evidence indicates that most IVF add-on therapies do not improve results, leading to calls for stricter national rules and better education for patients.

目前證據顯示，大多數 IVF 附加療法無法改善結果，因此各界呼籲建立更嚴格的全國規範並加強對患者的教育。